ArticleFrontiers in pharmacology2026

Incidence and risk factors of venous and arterial thromboembolism events in lung cancer patients treated with immune checkpoint inhibitors.

Guihua Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.